tesamorelin vs cjc ipamorelin CJC-1295: Research Compared differences between cjc-1295 ipamorelin tesamorelin

Guilliams M, De Kleer I, Henri S, et al

Using QQ plots and a univariate correlation test (Johnson and Wichern, 1998), we found these data not to be approximately normal nor consistently transformable to approximate normality for all three datasets (HC, BL, 4w)

In the myocardium, a reduction in LOX activity disrupts the connective tissue architecture and impairs contractile function [47]

Daily Dose: 2.67 mg (equivalent to 10 units / 0.10 mL), maintained throughout the full cycle Frequency: Administer once daily via subcutaneous injection, ideally at the same time each day Cycle Duration: 4-16 weeks of continuous use, followed by a 24 week break to assess response and support receptor recovery Injection Volume: Approximately 0.10 mL per dose, well within typical comfort limits for subcutaneous delivery (generally under 1.01.5 mL) Syringe Guidance: A 0.3 mL (30-unit) U-100 insulin syringe is recommended for improved accuracy when measuring small volumes Storage Instructions Proper storage is essential to maintain peptide stability and integrity

Dissolves quickly after a few shakes